GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE271nnn/GSE271663/primaryOK200TranscriptomicsMus musculus OtherExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271663GEOGSEfalseTumor-Suppressing Multi-Enterobacteria enhance the anti-PD-1/PD-L1 efficacy in microsatellite stable colorectal cancerGut microbiome significantly influences immunotherapy responses in colorectal cancer (CRC) treatment. While individual enterobacteria have been identified as enhancers of anti-PD-1/anti-PD-L1 therapy, the synergistic effects of multiple enterobacteria remain underexplored. To fill the gap, we introduced Tumor-Suppressing Multi-Enterobacteria (TSME), a consortium of nine beneficial intestinal probiotic strains, and investigated its impact on the anti-PD-1/anti-PD-L1 therapy for microsatellite stable (MSS) CRC. Using a tumor-bearing mouse model and genomic sequencing techniques, our research demonstrated that TSME significantly improved therapy efficacy by optimizing tumor immune microenvironment. Specifically, the addition of TSME notably increased CD8+ T infiltration, modulated cytokine profiles, and up-regulated crucial immune-related pathways, including TNF and JAK-STAT. Additionally, TSME altered intestinal microbial composition, enriching beneficial bacteria such as Akkermansia and Alistipes. These findings suggest that the well-engineered multi-enterobacteria could significantly enhance the effectiveness of immunotherapy for MSS CRC by synergistically modulating the immune and microbial landscapes.2026/04/26GSE271663GSM8381394GSM8381393GSM8381374GSM8381396GSM8381395GSM8381398GSM8381376GSM8381397GSM8381375GSM8381378GSM8381377GSM8381399GSM8381390GSM8381392GSM8381391GSM8381409GSM8381402GSM8381401GSM8381404GSM8381403GSM8381406GSM8381405GSM8381408GSM8381407GSM8381383GSM8381382GSM8381385GSM8381384GSM8381387GSM8381386GSM8381400GSM8381389GSM8381388GSM8381381GSM8381380GSM838137924247271663Mus musculus